Title :

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

Author(s) :

Langner-Lemercier, Sophie [Auteur]
Houillier, Caroline [Auteur]
Soussain, Carole [Auteur]
Ghesquieres, Herve [Auteur]
Chinot, Olivier [Auteur]
Taillandier, Luc [Auteur]
Soubeyran, Pierre [Auteur]
Lamy, Thierry [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Benouaich-Amiel, Alexandra [Auteur]
Ahle, Guido [Auteur]
Moles-Moreau, Marie-Pierre [Auteur]
Molucon-Chabrot, Cecile [Auteur]
Bourquard, Pascal [Auteur]
Damaj, Gandhi [Auteur]
Jardin, Fabrice [Auteur]
Larrieu, Delphine [Auteur]
Gyan, Emmanuel [Auteur]
Gressin, Remy [Auteur]
Jaccard, Arnaud [Auteur]
Choquet, Sylvain [Auteur]
Brion, Annie [Auteur]
Casasnovas, Olivier [Auteur]
Colin, Philippe [Auteur]
Reman, Oumedaly [Auteur]
Tempescul, Adrian [Auteur]
Marolleau, Jean-Pierre [Auteur]
Fabbro, Michel [Auteur]
Naudet, Florian [Auteur]
Hoang-Xuan, Khe [Auteur]
Houot, Roch [Auteur]

Journal title :

Neuro-oncology

Abbreviated title :

Neuro-Oncology

Volume number :

18

Pages :

1297-1303

Publication date :

2016

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is poorly defined, because randomized trials and large studies are lacking. The aim of this study was to analyze the characteristics, management, ...
Show more >BACKGROUND: Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is poorly defined, because randomized trials and large studies are lacking. The aim of this study was to analyze the characteristics, management, and outcome of R/R PCNSL patients after first-line therapy in a nationwide cohort. METHODS: We analyzed R/R PCNSL patients following first-line treatment who had been prospectively registered in the database of the French network for oculocerebral lymphoma (LOC) between 2011 and 2014. RESULTS: Among 563 PCNSL patients treated with first-line therapy, we identified 256 with relapsed (n = 93, 16.5%) or refractory (n = 163, 29.0%) disease. Patients who were asymptomatic at relapse/progression (25.5%), mostly diagnosed on routine follow-up neuroimaging, tended to have a better outcome. Patients who received salvage therapy followed by consolidation (mostly intensive chemotherapy plus autologous hematopoietic stem cell transplantation [ICT + AHSCT]) experienced prolonged survival compared with those who did not receive salvage or consolidation therapy. Independent prognostic factors at first relapse/progression were: KPS ≥ 70 vs KPS < 70), sensitivity to first-line therapy (relapsed vs refractory disease), duration of first remission (progression-free survival [PFS] ≥1 y vs <1 y), and management at relapse/progression (palliative care vs salvage therapy). Patients who relapsed early after first-line therapy (ie, PFS < 1 y) had a poor outcome, comparable to that of refractory patients. Conversely, patients experiencing late relapses (PFS ≥ 1 y) and/or undergoing consolidation with ICT + AHSCT experienced prolonged survival. CONCLUSIONS: About a third of PCNSL patients are primary refractory to first line treatment. We identified several independent prognostic factors that can guide the management of R/R PCNSL patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Innovation/évaluation des médicaments injectables

Submission date :

2019-02-26T17:07:26Z